1CIBIS-Ⅱ investigators and committees.The cardiac insufficiency bisoprolol study Ⅱ a randomizedtrial,Lancet,1999,353(9146):9.
2MERIT-HF study group.Effect of metoprolo CR/XL in chronic heart faifure:Metoprolol CR/XL randomized intervention trial in congestive heart failure.Lancet,1999.353:2001.
3Packer M.The neurohumoral hypothesis:a theory to explain the mechanism of disease progressioninheartfailure. JAM Coil Cardiol,1992,20:248.
4Talazzuoli A,CalabriaT et al.Effeect Ofcarvedilol therapy on restrictive diastolic filling pattern in chronicheartfailure. Am Heart J,2004,147(1):1.
5Gupta R,Tang WH,Yong JB et al.Patterns of betablocker utilization in patients with chronic heart failure:exterience from a stecialized outpatients heart clinic.Am heart J,2004,147(1):79.
6Metra,Nodari S,P'Aloia A et al.a rationale for the use of β-blocker as Standard trenment forheart failure.AM Heart J,2000,139:511.
7Parmly W W.Neuroendocrine changes in heart failure and their clincal Relevance.Clin Cardiol,1995,18(8):440.
8Pepper GS,Lee RW.sympathytic-activation in heart failure and its treatment with lB blockade.Arch Intern Med,1999,159(8):225.
9Squire I B,Banett D B.The rational use of β-adrenoceptor blockets in the treatment of heart failure.The changing face of an old therapy.Br J clin Pharmacol,2000.49:1.
10Rockmam HA,chien KR,choi DJ et al.Expression of a β-adrenergic receptor kinase Iinbibitor prevents the development of myocardial failure in gene targeted mice.Proc Natl Acad Sci USA,1998,95:7000.
